208 Late Breaking Abstracts treatment. However, with all three disease entities, iron deficiency/anemia is a frequent systemic complication. The underlying inflammatory state often leads to anemia of chronic disease, which is frequently associated with functional and/or absolute iron deficiency. Methods: We evaluated 3 non-interventional studies in ND-CKD, IBD and oncology. 719 anemic patients could be evaluated for effectiveness. Patients were known to the respective study center for at least 3 12 months. Aim of these studies was to examine the efficacy and safety of ferric carboxymaltose (FCM, ferinject ® ) in the clinical setting. Patients included in the analysis received at least one dose of FCM and were observed for 12 weeks. Results: On average, patients received 1333 mg (oncolog- ical malignancies), 870 mg (ND-CKD) and 1125 mg (IBD) iron. Mean Hb as well as iron parameters improved significantly in all three studies. Moreover, the majority of patients reported improvements in symptoms such as fatigue or lack of concentration (ND-CKD, IBD). Alternatively, the success of therapy was predominantly considered good or very good by the investigators (oncology). Study Hb (g/dl) Serum ferritin (ng/dl) TSAT (%) BOS EOS BOS EOS BOS EOS Oncology 10.0 11.5 362 1041 17.0 29.7 ND-CKD 10.1 11.8 140 313 17.4 31.2 IBD 10.0 12.3 42 103 15.1 25.2 TSAT: Transferrin saturation, BOS: Baseline; EOS: End of Study. Conclusion: FCM effectively corrected signs and symp- toms of iron deficiency anemia in chronic disease. Irrespective of the underlying disease, patients received on average 1000 mg of iron (847 1333 mg). Disclosure of Interest: J. Stein Grant/Research Support from: Vifor Pharma, Consultant for: Vifor Pharma, Speakers Bureau: Vifor Pharma, A. Dignass Speakers Bureau: Vifor Pharma, R. Schaefer Speakers Bureau: Vifor Pharma, N. Marschner Consultant for: Vifor Pharma, R. Rohrberg Consultant for: Vifor Pharma, H.Tesch Consultant for: Vifor Pharma, S. Weber-Mangal Other: Vifor Pharma, T. Steinmetz Consultant for: Vifor Pharma, Other: Vifor Pharma LB009-SUN IS AMOUNT AND DISTRIBUTION OF PROTEIN INTAKE ASSOCIATED WITH FRAILTY? J. Bollwein 1 , R. Diekmann 1 , M. Kaiser 1 , J. Bauer 2 , C. Sieber 1 , D. Volkert 1 . 1 Department for internal medicine (Geriatrics), FAU, Institute for Biomedicine of Aging, N¨ urnberg, 2 Clinic for Geriatrics, Klinikum Oldenburg GmbH, Oldenburg, Germany Rationale: Amount and distribution of protein intake (PI) are discussed to be of great relevance for muscle mass and, thus, could also be important for the development of frailty. This cross-sectional study investigates the association between amount and distribution of protein intake and frailty in community-dwelling older adults. Methods: In 195 volunteers aged 75 y and older (66% fe- males, 83±4y, BMI 27.0±3.7 kg/m 2 ) the habitual con- sumption of 104 foods was assessed using a food- frequency questionnaire (EPIC). For 46 main protein sources also the time of consumption (morning, noon, evening) was requested. PI was calculated from standard portion sizes using the German nutrient database BLS 2.0. Three frailty classes (FC) were determined as presence of 0, 1 2 or 3 of the five criteria: weight loss >4.5 kg in the last year, exhaustion, low physical activity, low handgrip strength and slow walking speed. Median (min. max.) PI in g/d, g/kg body weight (BW) and as percentage of energy intake (E%) as well as distribution of PI over the day was compared between the FC by Kruskal Wallis test. Results: Median daily PI was 77.5 (38.5 131.5) g, 1.0 (0.58 2.27) g/kg BW and 15.9 (11.2 21.8) E% without differences between the FC. The main protein sources covered a median of 74% (46 91) of total PI. With increasing frailty, the percentage of protein ingested in the morning decreased [18% (3 47) vs. 15% (0 43) vs. 12% (0 30), p < 0.05], whereas it increased at noon [55% (17 80) vs. 61% (0 83) vs. 61% (32 85), p < 0.05]. Conclusion: In this sample of community-dwelling elderly no association between amount of protein intake and frailty was observed, whereas the frailty-classes differed in their proportional protein distribution in the morning and at noon. Further research on the effect of protein intake on frailty is needed. Disclosure of Interest: None Declared LB010-SUN MALNUTRITION IN CANADIAN HOSPITALS: PRELIMINARY RESULTS FROM THE CANADIAN MALNUTRITION TASK FORCE (CMTF) J.P. Allard 1 , K.N. Jeejeebhoy 2 , L. Gramlich 3 , D. Duerksen 4 , H. Payette 5 , P. Bernier 6 , H. Keller 7 , M. Laporte 8 . 1 Medicine, University Health Network, 2 Medicine, St. Michael’s Hospital, Toronto, 3 Department of Nutrition, University of Alberta Hospitals, Edmonton, 4 Medicine, University of Manitoba, Winnipeg, 5 Medicine, Universit´ e de Sherbrooke, Sherbrooke, 6 Medicine, McGill University, Montreal, 7 Nutrition, University of Guelph, Guelph, 8 Nutrition, Campbelton Regional Hospital, Campbelton, Canada Background: The prevalence of hospital malnutrition is unknown in Canada. Objectives: To assess in Canadian hospitals, the preva- lence of malnutrition, changes in nutritional status and effects of malnutrition on outcomes. Methods: Prospective cohort study. So far, 6 hospitals par- ticipated. Patients underwent a nutritional assessment at admission and discharge and are followed until 30 days post-discharge. Measurements: SGA, anthropometry, Charlson comorbidity index (CCI), plasma C-reactive protein (CRP) and albumin. Outcomes: in-hospital and 30- days mortality, length of stay and 30-day re-admission rate. Comparisons between SGA groups and comparison between discharge and baseline were performed. Results showed as mean+SEM or median (range). Results: So far 160 patients completed: 63.2+15.8 years; Male:Female 43.4%:56.6%. At admission: the most frequent diagnosis was gastrointestinal disorder (34%); CCI was 2 (0 14); 55.0%, 35.6% and 9.4% of patients were SGA A, B, and C respectively. During hospital- ization, CRP decreased from 30.2 (0.2 339.9) to 12.4